Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ESBRIET vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pirfenidone inhibits TGF-β stimulated collagen production and reduces fibroblast proliferation, exhibiting anti-inflammatory and antifibrotic effects in pulmonary fibrosis.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Idiopathic pulmonary fibrosis (IPF)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
801 mg three times daily orally with food.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal elimination half-life is approximately 3 hours (range 1.5-5 hours) in healthy adults. In patients with idiopathic pulmonary fibrosis, half-life is similar but exhibits interindividual variability.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Primarily hepatic via CYP1A2 (major), with minor contributions from CYP2C9, CYP2C19, CYP2D6, and CYP2E1.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal excretion of parent drug and metabolites accounts for approximately 99% of elimination, with about 82% recovered in urine and 1% in feces. Pirfenidone is extensively metabolized, with less than 1% excreted unchanged.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Protein binding is approximately 50-58%, primarily to albumin.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Volume of distribution is approximately 1.0 L/kg, indicating extensive tissue distribution.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Oral bioavailability is approximately 80% (range 70-90%) under fed conditions; food reduces peak concentration but increases total exposure.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
GFR 30-50 m L/min: 267 mg three times daily; GFR < 30 m L/min: not recommended.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
Child-Pugh A: 801 mg three times daily; Child-Pugh B: 267 mg three times daily; Child-Pugh C: contraindicated.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Not established; safety and efficacy in pediatric patients have not been studied.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
No specific dose adjustment recommended; monitor renal function and consider lower starting dose due to age-related decline in renal function.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
None
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Hepatotoxicity: monitor liver function tests before and during treatment; discontinue if significant elevation.,Photosensitivity and rash: avoid sun exposure; use sunscreen.,Gastrointestinal effects: nausea, diarrhea, dyspepsia; take with food.,Elevated liver enzymes: dose reduction or interruption may be required.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Severe hepatic impairment (Child-Pugh Class C),Severe renal impairment requiring dialysis,History of hypersensitivity to pirfenidone or any excipient
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Take with meals to reduce GI intolerance. Grapefruit and grapefruit juice may increase pirfenidone blood levels and should be avoided. Avoid smoking as it induces CYP1A2 and may reduce drug efficacy.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Pirfenidone is teratogenic in animal studies, causing fetal malformations and embryotoxicity at clinically relevant exposures. There are no adequate human studies. Use during pregnancy is contraindicated; effective contraception is required before and during treatment. First trimester carries the highest risk for major congenital anomalies; second and third trimester risks include fetal growth restriction and potential pulmonary toxicity.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
No human data on milk excretion; animal studies show drug and metabolites present in breast milk. Unknown M/P ratio. Risk of infant toxicity cannot be excluded. Breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No established dosing guidelines for pregnancy. Significant pharmacokinetic changes (increased volume of distribution, renal clearance) may reduce drug exposure. Theoretical adjustments are not recommended due to unknown safety; therapy should be discontinued if pregnancy occurs. If continuation is deemed unavoidable, dose individualization based on therapeutic drug monitoring is suggested but unvalidated.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Pirfenidone (Esbriet) is an antifibrotic agent approved for idiopathic pulmonary fibrosis (IPF). It reduces decline in lung function but does not reverse fibrosis. Monitor liver function tests (LFTs) monthly for 6 months then every 3 months due to risk of hepatotoxicity. Photosensitivity is common; advise strict sun avoidance and broad-spectrum sunscreen. Dosage titration over 14 days reduces GI side effects. Avoid use with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) as they increase pirfenidone exposure.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Take with food to reduce nausea and upset stomach.,Avoid sun exposure; wear protective clothing and apply sunscreen daily due to risk of severe sunburn.,Do not stop or change dose without consulting your doctor; taper is not required but missed doses should be skipped.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, fatigue, or abdominal pain.,Avoid smoking and grapefruit products as they may affect drug levels.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ESBRIET vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
ESBRIET is a Antifibrotic that works by Pirfenidone inhibits TGF-β stimulated collagen production and reduces fibroblast proliferation, exhibiting anti-inflammatory and antifibrotic effects in pulmonary fibrosis.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ESBRIET and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ESBRIET is: 801 mg three times daily orally with food.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ESBRIET and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ESBRIET is classified as Category C. Pirfenidone is teratogenic in animal studies, causing fetal malformations and embryotoxicity at clinically relevant exposures. There are no adequate human studies. Use during pregn. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.